Akoya Biosciences, Inc. (AKYA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 1.36 |
| Open | 1.29 |
| Day High | 1.29 |
| Day Low | 1.29 |
| 52-Week High | 3.42 |
| 52-Week Low | 0.93 |
| Volume | 715,252 |
| Average Volume | 582,118 |
| Market Cap | 64.44M |
| PE | -1.34 |
| EPS | -0.96 |
| Moving Average 50 Days | 1.22 |
| Moving Average 200 Days | 2.04 |
| Change | -0.07 |
Data not available
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025
GlobeNewswire Inc.
Apr 24, 2025 12:00 PM GMT
ADC assay now available through ABS; customer study proves IO60 is a spatial workhorseMARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, today announced the availability of a
Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
GlobeNewswire Inc.
Apr 24, 2025 12:00 PM GMT
>8,500 samples and 100 million cells of high resolution and fully annotated spatial proteomics data availableMARLBOROUGH, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Enable Med
Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore
GlobeNewswire Inc.
Apr 23, 2025 12:00 PM GMT
The STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study is a multi-institutional study led by STCC with the goal of identifying predictors of PD1 immunotherapy response in an Asian real-world setting, bringing together Singapore’s public healt